Search

Clinical trials

The advance of highly innovative, increasingly personalized therapies in hematology requires novel clinical trial designs and more flexible, adaptive regulatory frameworks and improved data generation to support decision making both during and after clinical studies.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Release of the First Handbook on CAR-T Cells in Europe

Barcelona, 9, February, 2022 – The EBMT and EHA are proud to announce the release of the first-ever open-access book on CAR-T cells to be officially launched during the EBMT-EHA 4th European CAR-T Cell Meeting (Feb 10-12, 2022, Virtual).

Read more

Major Conference: innovation and patient access to personalised medicine

The meeting will bring together researchers, patients, physicians, regulators and politicians, to explore the current barriers and how they can be dismantled.

Read more

Personalized medicine promises radical improvements to healthcare in Europe

And the precision that personalised medicine will bring good prospects for better use of resources.

Read more

Dutch scientists propose algorithm to keep drugs affordable and accessible

May 8, 2018, The Hague - An important contribution to the debate about the affordability and accessibility of innovative medicines appeared in Nature Reviews, proposing the adoption of a novel model of price setting with examples of implementation.

Read more